Ferring Statement on the COVID-19 (novel coronavirus disease) Pandemic and Reproductive Medicine
Saint-Prex, Switzerland – 18 March, 2020
The health and safety of our patients, our employees and their families are Ferring’s number one priority. As the situation regarding COVID-19 (novel coronavirus disease) is evolving rapidly, Ferring is committed to following appropriate global, regional and local medical authority guidance to prevent infection spread and to keep patients, our employees and their families safe.
In line with the current positions from scientific societies on patients seeking or undergoing fertility treatment, including from the European Society of Human Reproduction and Embryology (ESHRE) and the American Society of Reproductive Medicine (ASRM), Ferring is now working to temporarily halt recruitment or postpone our clinical trials in fertility as necessary in impacted countries.
In addition to policies to protect our employees and prevent infection spread, we have also put in place plans to avoid disruption in manufacturing and ensure continuity of supply of our treatments to doctors and patients around the world. However, we unfortunately cannot rule out a future impact on our business as the situation is rapidly evolving.
Our thoughts are with the people and families affected by COVID-19 around the world, including our patients and those working tirelessly to address the pandemic.
We remain committed to building families worldwide and look forward to continuing our research in the area of reproductive medicine and maternal health when the current situation improves.
If you are personally impacted by this situation and have questions for Ferring, contact us to get in touch with our teams.